| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFI35 |
| Uniprot No | P80217 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-286aa |
| 氨基酸序列 | SAPLDAALHALQEEQARLKMRLWDLQQLRKELGDSPKDKVPFSVPKIPLVFRGHTQQDPEVPKSLVSNLRIHCPLLAGSALITFDDPKVAEQVLQQKEHTINMEECRLRVQVQPLELPMVTTIQMSSQLSGRRVLVTGFPASLRLSEEELLDKLEIFFGKTRNGGGDVDVRELLPGSVMLGFARDGVAQRLCQIGQFTVPLGGQQVPLRVSPYVNGEIQKAEIRSQPVPRSVLVLNIPDILDGPELHDVLEIHFQKPTRGGGEVEALTVVPQGQQGLAVFTSESG |
| 预测分子量 | 37.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFI35重组蛋白的3-4条参考文献示例(部分信息为示例性概括，实际文献需通过学术数据库验证)：
---
1. **文献名称**：*"Expression and functional characterization of recombinant human IFI35 in antiviral immune responses"*
**作者**：Li X, Chen Y, Wang J
**摘要**：本研究成功在大肠杆菌中表达并纯化重组人IFI35蛋白，证实其通过抑制病毒RNA复制发挥抗病毒作用，并增强干扰素信号通路相关分子(如STAT1)的活性。
2. **文献名称**：*"IFI35 recombinant protein attenuates NF-κB-mediated inflammatory responses in macrophages"*
**作者**：Zhang R, Liu T, Zhou M
**摘要**：通过体外实验发现，重组IFI35蛋白可抑制LPS诱导的巨噬细胞炎症反应，机制涉及阻断NF-κB信号通路的活化，提示IFI35在自身免疫性疾病中的潜在治疗价值。
3. **文献名称**：*"Structural insights into IFI35 protein by recombinant expression and crystallography"*
**作者**：Smith A, Patel K, Kim H
**摘要**：首次报道IFI35重组蛋白的晶体结构，揭示其N端和C端结构域的关键相互作用，为解析其与病毒蛋白或宿主因子的结合机制提供结构基础。
4. **文献名称**：*"Recombinant IFI35 regulates cell apoptosis via modulating mitochondrial dynamics"*
**作者**：Wang L, Deng Y, Xu S
**摘要**：研究表明，外源性重组IFI35通过调控线粒体分裂蛋白Drp1的活性，抑制病毒感染导致的细胞凋亡，突显其在细胞存活中的双重作用。
---
**注**：以上为模拟参考文献，实际研究中请通过PubMed、Web of Science等平台检索真实文献(关键词：IFI35. recombinant protein, interferon-induced protein 35)。
**Background of IFI35 Recomcombinant Protein**
IFI35 (Interferon-induced protein 35), also known as IFI35 or NMI (N-myc interactor), is a protein encoded by the *IFI35* gene in humans. It belongs to the family of interferon-stimulated genes (ISGs), which are upregulated in response to interferon signaling during viral infections and immune challenges. Initially identified as a binding partner of N-myc oncoprotein, IFI35 has since been implicated in diverse cellular processes, including immune regulation, apoptosis, and antiviral defense. Its expression is strongly induced by type I and type II interferons, positioning it as a critical mediator in innate immunity and inflammatory responses.
Structurally, IFI35 contains a coiled-coil domain and a leucine zipper motif, facilitating protein-protein interactions. It forms homodimers or heterodimers with other proteins, such as IFI16. to modulate transcriptional activity or signal transduction pathways. Studies suggest IFI35 regulates NF-κB and STAT signaling, influencing cytokine production and immune cell functions. However, its role appears context-dependent, with evidence of both pro-inflammatory and immunosuppressive effects depending on cellular conditions.
Recombinant IFI35 protein is engineered for research to study its biochemical properties, interactions, and therapeutic potential. Produced via expression systems like *E. coli* or mammalian cells, it retains functional domains for in vitro assays, such as binding studies, enzymatic activity tests, or immune response modulation experiments. Notably, IFI35 has been linked to autoimmune diseases (e.g., lupus) and cancer progression, where dysregulation correlates with tumor growth or metastasis. Its dual role in promoting or inhibiting viral replication in different pathogens (e.g., HIV, hepatitis viruses) also makes it a focus for antiviral drug development.
Despite progress, IFI35's precise mechanisms remain incompletely understood. Ongoing research aims to clarify its regulatory networks and explore its potential as a diagnostic marker or therapeutic target in immune disorders and oncology.
×
